Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

Administration of semaglutide before metabolic and bariatric surgery does not confer benefits for overall weight loss, ...

A RETROSPECTIVE study conducted by Mass General Brigham researchers has found that taking semaglutide before bariatric ...

Experts stress that obesity is a disease, not a lifestyle choice, and call for better access to pharmacological and surgical ...

Semaglutide wasn't approved for obesity at higher doses until 2021, and therefore maximum weight-loss doses were often not reached by patients, Sheu's group pointed out. Also, since the cohort was ...

Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...